Basic questionnaires to assess the quality of life in patients with multiple sclerosis

Abstract


Quality of life is one of the most significant indicators of the effectiveness of care for patients with multiple sclerosis. The aim of this work was to summarize the available literature on the characteristics of the main questionnaires used to assess QOL in patients with multiple sclerosis. Materials and methods. The search for relevant literary sources was conducted in the PubMed bibliographic database. The search queries used the keywords: «multiple sclerosis», «questionnaires», «quality of life», and the English-language names of the tests. Publications were selected by title and abstract content. Results. The scientific literature encompasses a wide range of questionnaires for assessing the condition and quality of life of patients with MS. The work considers the main tests. Some of them include a standard block of general questions, for example, SF-36, allowing for comparison between patients with various diseases and healthy subjects. It is noted that the design of questionnaires with the inclusion of general and specialized blocks is very convenient for simultaneously obtaining diverse, comprehensive assessments of the course of MS. In practice, the choice of a specific questionnaire depends on the goals and objectives of its use. Discussion. Some questionnaires are more often used in clinical and epidemiological studies, while others have already been introduced into everyday clinical practice. Before introducing new questionnaires written in foreign languages into the Russian healthcare system, they need to be adapted. Validation of questionnaires in regional healthcare will open up new prospects for their use in regular clinical practice.

About the authors

Dmitry A. Andreev

Research Institute for Healthcare Organization and Medical Management of Moscow Healthcare Department, Moscow, Russia

Email: andreevda@zdrav.mos.ru

References

  1. Thakolwiboon S., Mills E. A., Yang J. et al. Immunosenescence and multiple sclerosis: inflammaging for prognosis and therapeutic consideration. Front. Aging. 2023;4:1234572. doi: 10.3389/fra-gi.2023.1234572
  2. Boyko A., Melnikov M. Prevalence and incidence of multiple sclerosis in Russian Federation: 30 years of studies. Brain Sci. 2020;10(5):305. doi: 10.3390/brainsci10050305
  3. Raji I., El Harch I., Ragala M. E.A. et al. The impact of therapeutic education programs on the quality of life of patients with multiple sclerosis: Protocol of a systematic review. J. Educ. Health Promot. 2023;12:264. doi: 10.4103/jehp.jehp_331_23
  4. Simpson R., Posa S., Langer L. et al. A systematic review and meta-analysis exploring the efficacy of mindfulness-based interventions on quality of life in people with multiple sclerosis. J. Neurol. 2023;270(2):726–745. doi: 10.1007/s00415-022-11451-x
  5. Brichetto G., Zaratin P. Measuring outcomes that matter most to people with multiple sclerosis: the role of patient-reported outcomes. Curr. Opin. Neurol. 2020;33(3):295–299. doi: 10.1097/WCO.0000000000000821
  6. Flores V. A., Šilić P., DuBose N. G. et al. Effects of aerobic, resistance, and combined exercise training on health-related quality of life in multiple sclerosis: systematic review and meta-analysis. Mult. Scler. Relat. Disord. 2023;75:104746. doi: 10.1016/j.msard.2023.104746
  7. Maurino J., Martínez-Ginés M. L., García-Domínguez J. M. et al. Workplace difficulties, health-related quality of life, and perception of stigma from the perspective of patients with Multiple Sclerosis. Mult. Scler. Relat. Disord. 2020;41:102046. doi: 10.1016/j.msard.2020.102046
  8. D’Amico E., Haase R., Ziemssen T. Review: patient-reported outcomes in multiple sclerosis care. Mult. Scler. Relat. Disord. 2019;33:61–66. doi: 10.1016/j.msard.2019.05.019
  9. Beckmann H., Heesen C., Augustin M., Blome C. The 27-Item Multiple Sclerosis Quality of Life Questionnaire: a new brief measure including treatment burden and work life. Int. J. MS Care. 2022;24(4):147–153. doi: 10.7224/1537-2073.2020-088
  10. Opara J. A., Jaracz K., Brola W. Quality of life in multiple sclerosis. J. Med Life. 2010;3(4):352–358.
  11. Andreev D. A., Zavyalov A. A., Kashurnikov A. Yu. Basic versions of the EQ-5D questionnaire are standard international tools for assessing the quality of life. A brief review of the literature. The health of the metropolis. 2021;2(1):62–69. (In Russian).
  12. Healy B. C., Liu Y., Winston-Khan S. et al. Association between PROMIS10, SF-36 and NeuroQoL in persons with multiple sclerosis. Mult. Scler. Relat. Disord. 2023;79:105003. doi: 10.1016/j.msard.2023.105003
  13. Hoogs M., Kaur S., Smerbeck A. et al. Cognition and physical disability in predicting health-related quality of life in multiple sclerosis. Int. J. MS Care. 2011;13(2):57–63. doi: 10.7224/1537-2073-13.2.57
  14. Skevington S. M., Lotfy M., O’Connell K. A. The World Health Organization’s WHOQOL-BREF quality of life assessment: psychometric properties and results of the international field trial. A report from the WHOQOL group. Qual. Life Res. 2004;13(2):299–310. doi: 10.1023/B:QURE.0000018486.91360.00
  15. Pomeroy I. M., Tennant A., Mills R. J., Young C. A. The WHOQOL-BREF: a modern psychometric evaluation of its internal construct validity in people with multiple sclerosis. Qual. Life Res. 2020;29(7):1961–1972. doi: 10.1007/s11136-020-02463-z
  16. Kaplan R. M., Bush J. W., Berry C. C. Health status: types of validity and the index of well-being. Health Serv. Res. 1976;11(4):478–507.
  17. Hadgkiss E. J., Jelinek G. A., Weiland T. J. et al. Health-related quality of life outcomes at 1 and 5 years after a residential retreat promoting lifestyle modification for people with multiple sclerosis. Neurol. Sci. 2013;34(2):187–195. doi: 10.1007/s10072-012-0982-4
  18. Drulovic J., Bursac L. O., Milojkovic D. et al. MSQoL-54 predicts change in fatigue after inpatient rehabilitation for people with multiple sclerosis. Disabil. Rehabil. 2013;35(5):362–366. doi: 10.3109/09638288.2012.704122
  19. Vickrey B. G., Hays R. D., Harooni R. et al. A health-related quality of life measure for multiple sclerosis. Qual. Life Res. 1995;4(3):187–206. doi: 10.1007/BF02260859
  20. Estiasari R., Melani S., Kusumawardhani A. et al. Validation of the Indonesian version of multiple sclerosis quality of life-54 (MSQOL-54 INA) questionnaire. Health Qual. Life Outcomes. 2019;17(1):120. doi: 10.1186/s12955-019-1190-1
  21. Yang S., Li X., Wang J. et al. Sphingosine-1-phosphate receptor modulators versus interferon beta for the treatment of relapsing-remitting multiple sclerosis: findings from randomized controlled trials. Neurol. Sci. 2022;43(6):3565–3581. doi: 10.1007/s10072-022-05988-y
  22. Breuer B., Pappagallo M., Knotkova H. et al. A randomized, double-blind, placebo-controlled, two-period, crossover, pilot trial of lamotrigine in patients with central pain due to multiple sclerosis. Clin. Ther. 2007;29(9):2022–2030. doi: 10.1016/j.clinthera.2007.09.023
  23. Gold S. M., Heesen C., Schulz H. et al. Disease specific quality of life instruments in multiple sclerosis: validation of the Hamburg Quality of Life Questionnaire in Multiple Sclerosis (HAQUAMS). Mult. Scler. 2001;7(2):119–130. doi: 10.1177/135245850100700208
  24. Schäffler N., Schönberg P., Stephan J. et al. Comparison of patient-reported outcome measures in multiple sclerosis. Acta Neurol. Scand. 2013;128(2):114–121. doi: 10.1111/ane.12083
  25. Cella D. F., Dineen K., Arnason B. et al. Validation of the Functional Assessment of Multiple Sclerosis quality of life instrument. Neurology. 1996;47(1):129–139. doi: 10.1212/wnl.47.1.129
  26. Fischer J. S., LaRocca N. G., Miller D. M. et al. Recent developments in the assessment of quality of life in multiple sclerosis (MS). Mult. Scler. 1999;5(4):251–259. doi: 10.1177/135245859900500410
  27. Simeoni M., Auquier P., Fernandez O. et al. Validation of the Multiple Sclerosis International Quality of Life questionnaire. Mult. Scler. 2008;14(2):219–230. doi: 10.1177/1352458507080733
  28. Fernández O., Fernández V., Baumstarck-Barrau K. et al. Validation of the spanish version of the Multiple Sclerosis International Quality of Life (Musiqol) questionnaire. BMC Neurol. 2011;11:127. doi: 10.1186/1471-2377-11-127
  29. Regnault A., Loubert A., Brennan R. et al. Does the Multiple Sclerosis Impact Scale-29 (MSIS-29) have the range to capture the experience of fully ambulatory multiple sclerosis patients? Learnings from the ASCLEPIOS studies. Mult. Scler. J. Exp. Transl. Clin. 2023;9(3):20552173231201424. doi: 10.1177/20552173231201422
  30. Hobart J., Lamping D., Fitzpatrick R. et al. The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure. Brain. 2001;124(Pt 5):962–973. doi: 10.1093/brain/124.5.962
  31. van Leeuwen L. M., Mokkink L. B., Kamm C. P. et al. Measurement properties of the Arm Function in Multiple Sclerosis Questionnaire (AMSQ): a study based on Classical Test Theory. Disabil. Rehabil. 2017;39(20):2097–2104. doi: 10.1080/09638288.2016.1213898

Statistics

Views

Abstract - 0

PDF (Russian) - 0

Cited-By


PlumX

Dimensions


Copyright (c) 2024 АО "Шико"

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Mailing Address

Address: 105064, Moscow, st. Vorontsovo Pole, 12, building 1

Email: redactor@remedium-journal.ru

Phone: +7(495) 917-48-86



Principal Contact

Sherstneva Elena Vladimirovna
EXECUTIVE SECRETARY
FSSBI «N.A. Semashko National Research Institute of Public Health»

105064, Vorontsovo Pole st., 12, Moscow


Email: redactor@remedium-journal.ru

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies